Sources

13 Total Sources

FDA Approves Sarclisa Escena for 3 Multiple Myeloma Uses

Center100%
Monthly Prescribing Reference7d ago
FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma Treatment
PharmTech7d ago
The Implications of Isatuximab-irfc's FDA Approval for Multiple Myeloma | Pharmaceutical Technology
Oncology News Central7d ago
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma Indications
Oncodaily6d ago
FDA Approved Subcutaneous Isatuximab: Advancing Anti-CD38 Therapy Delivery in Multiple Myeloma - OncoDaily
AJMC.com Managed Markets Network7d ago
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma | AJMC
Pharmaceutical Executive7d ago
FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma | PharmExec
Curetoday.com7d ago
FDA Approves Sarclisa Escena as a New Under the Skin Treatment Option for Multiple Myeloma | CURE
GuruFocus.com7d ago
Sanofi (SNY) Secures FDA Approval for Subcutaneous Sarclisa Esce
Marketscreener.com7d ago
Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector | MarketScreener
Pharmacy Times7d ago
Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma | Pharmacy Times
pharmanow.live7d ago
Sanofi FDA Approval: Subcutaneous Isatuximab-irfc CirCLIQ OBDS | Pharma Now
linkedin7d ago
Super excited! Sarclisa Escena is approved in the US as first anticancer treatment administered via on-body injector, advancing patient and provider centric innovation. | Nihal Tugcu
X7d ago
Isatuximab subcutaneously with the on-body delivery system is now @US_FDA ✓ for multiple myeloma" — @OncBrothers FDA approved (Jul 10) @sanofi's Sarclisa Escena — the first anticancer treatment via an on-body injector —